Epigenetic Reprogramming in Cancer
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
The demonstration of induced pluripotency and direct lineage conversion has led to remarkable insights regarding the roles of transcription factors and chromatin regulators in mediating cell state transitions. Beyond its considerable implications for regenerative medicine, this body of work is highly relevant to multiple stages of oncogenesis, from the initial cellular transformation to the hierarchical organization of established malignancies. Here, we review conceptual parallels between the respective biological phenomena, highlighting important interrelationships among transcription factors, chromatin regulators, and preexisting epigenetic states. The shared mechanisms provide insights into oncogenic transformation, tumor heterogeneity, and cancer stem cell models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was demonstrated that ipilimumab induces the expression of EZH2, a key epigenetic enzyme that plays an important role in cellular plasticity (115-118).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [117]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Expression of a single transfected cDNA converts fibroblasts to myoblasts
Davis, R. L., Weintraub, H., & Lassar, A. B. (1987) · Cell · doi:10.1016/0092-8674(87)90585-x · Cited by 3,385
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Loss of the Suv39h Histone Methyltransferases Impairs Mammalian Heterochromatin and Genome Stability
Peters, A. H. F. M., O'Carroll, D., Scherthan, H., Mechtler, K., Sauer, S., Schöfer, C., Weipoltshammer, K., Pagani, M., Lachner, M., Kohlmaier, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00542-6 · Cited by 1,766
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Cited by
Items 201–300 of 702
Hahn, M. A., Li, A. X., Wu, X., Yang, R. H., Drew, D. A., Rosenberg, D. W., & Pfeifer, G. P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3147 · Cited by 55
“Recently, genome sequencing has identified a high frequency of mutations in epigenetic regulatory factors or chromatin structural elements in human malignancies (24, 25).”
Holt, M. T., David, Y., Pollock, S., Tang, Z., Jeon, J., Kim, J., Roeder, R. G., & Muir, T. W. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1504483112 · Cited by 52
SOX7: from a developmental regulator to an emerging tumor suppressor.
Stovall, D. B., Cao, P. D., & Sui, G. (2014) · PubMed · doi:10.14670/hh-29.10.439 · Cited by 61
“Multiple mechanisms contribute to the suppression of gene expression, including allele deletion, promoter methylation, histone modifications, mRNA translation or stability, and protein turnover rates (Suva et al., 2013).”
Deep Learning of Cancer Stem Cell Morphology Using Conditional Generative Adversarial Networks
Aida, S., Okugawa, J., Fujisaka, S., Kasai, T., Kameda, H., & Sugiyama, T. (2020) · Biomolecules · doi:10.3390/biom10060931 · Cited by 53
“The similarity between the reprogramming mechanisms of iPS cells by transcription factors and the mechanisms of cell transformation to CSC has been of interest [5].”
BackgroundDysregulated epigenetic modifications in psoriasis
Zeng, C., Tsoi, L. C., & Gudjonsson, J. E. (2021) · Experimental Dermatology · doi:10.1111/exd.14332 · Cited by 62
PRMT1 inhibition promotes ferroptosis sensitivity via ACSL1 upregulation in acute myeloid leukemia
Zhou, L., Jia, X., Shang, Y., Sun, Y., Liu, Z., Liu, J., Jiang, W., Deng, S., Yao, Q., Chen, J., et al. (2023) · Molecular Carcinogenesis · doi:10.1002/mc.23550 · Cited by 53
The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer
Magnani, L., Patten, D. K., Nguyen, V. T. M., Hong, S.-P., Steel, J. H., Patel, N. R., Lombardo, Y., Faronato, M., Gomes, A., Woodley, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4243 · Cited by 55
“It will be interesting to investigate the role of pioneers factors in alternative ERα pathways, including metabolic induced ERα signaling [33, 34] Genetic aberration targeting chromatin remodelers and other proteins involved in epigenetic processes are now frequently recognized as major drivers in several types of can…”
BackgroundZhao, W., Ma, N., Wang, S., Mo, Y., Zhang, Z., Huang, G., Midorikawa, K., Hiraku, Y., Oikawa, S., Murata, M., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0554-9 · Cited by 51
“Epigenetic changes, which involve DNA methylation and histone modifications, play critical roles in the onset and progression of cancer and other diseases [4, 5].”
Jin, W., Zhang, Y., Zhao, Z., & Gao, M. (2024) · Theranostics · doi:10.7150/thno.93962 · Cited by 54
Tang, J., Amin, M. A., & Campian, J. L. (2025) · Cells · doi:10.3390/cells14080562 · Cited by 65
“Histone modifications influence chromatin structure and accessibility of transcription factors, affecting gene expression profiles associated with stemness and differentiation [66].”
The Molecular Mechanism of Metabolic Remodeling in Lung Cancer
Chang, L., Fang, S., & Gu, W. (2020) · Journal of Cancer · doi:10.7150/jca.31406 · Cited by 52
“Metabolic remodeling takes place from the outset and throughout the development of LC, playing an important role in the evolution of LC [5].”
BackgroundG9a controls pluripotent-like identity and tumor-initiating function in human colorectal cancer
Bergin, C. J., Zouggar, A., Haebe, J. R., Masibag, A. N., Desrochers, F. M., Reilley, S. Y., Agrawal, G., & Benoit, Y. D. (2020) · Oncogene · doi:10.1038/s41388-020-01591-7 · Cited by 51
Cunha, S., Lin, Y., Goossen, E. A., DeVette, C. I., Albertella, M. R., Thomson, S., Mulvihill, M. J., & Welm, A. L. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.010 · Cited by 54
Wang, C., Sun, H., Gao, X., Ren, N., Sheng, Y., Wang, Z., Zheng, Y., Wei, J., Zhang, K., Yu, X., et al. (2016) · PubMed · Cited by 59
Noberini, R., Osti, D., Miccolo, C., Richichi, C., Lupia, M., Corleone, G., Hong, S.-P., Colombo, P., Pollo, B., Fornasari, L., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky224 · Cited by 49
The DNMT3A R882H mutant displays altered flanking sequence preferences
Emperle, M., Rajavelu, A., Kunert, S., Arimondo, P. B., Reinhardt, R., Jurkowska, R. Z., & Jeltsch, A. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky168 · Cited by 62
SOX transcription factors and glioma stem cells: Choosing between stemness and differentiation
Stevanović, M. J., Kovačević‐Grujičić, N., Mojsin, M. M., Milivojević, M., & Drakulić, D. (2021) · World Journal of Stem Cells · doi:10.4252/wjsc.v13.i10.1417 · Cited by 63
E2F4 regulatory program predicts patient survival prognosis in breast cancer
Khaleel, S. S., Andrews, E. H., Ung, M. H., DiRenzo, J., & Cheng, C. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0486-7 · Cited by 49
“Unsurprisingly, aberrant expression or mutation of TFs or of their upstream signaling proteins has been implicated in an array of human diseases, including cancer [18-20].”
BackgroundToward a Unified Theory of Aging and Regeneration
West, M. D., Sternberg, H., Labat, I., Janus, J., Chapman, K. B., Malik, N. N., de Grey, A. D. N. J., & Larocca, D. (2019) · Regenerative Medicine · doi:10.2217/rme-2019-0062 · Cited by 50
Chernov, A. V., Reyes, L., Xu, Z., Gonzalez, B., Golovko, G., Peterson, S. N., Perucho, M., Fofanov, Y., & Strongin, A. Y. (2015) · Epigenetics · doi:10.1080/15592294.2015.1020000 · Cited by 46
“Importantly, in normal human cells, the methylation of CG sites is strictly controlled in a developmental manner and unregulated CG hypermethylation is deleterious to the cell.(47) We estimated that in Mhy1-expressing fibrosarcoma cells a number of methylation marks in the nonrepetitive DNA regions increased >1.”
BackgroundReprogramming activity of NANOGP8, a NANOG family member widely expressed in cancer
Palla, A. R., Piazzolla, D., Abad, M., Li, H., Domínguez, O., Schönthaler, H. B., Wagner, E. F., & Serrano, M. (2013) · Oncogene · doi:10.1038/onc.2013.196 · Cited by 49
Nina, K. L., Lim, J. K., Leong, M. F., Sandanaraj, E., Ang, B. T., Tang, C., & Wan, A. C. A. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.11.031 · Cited by 52
Schultz, L. E., Haltom, J., de Almeida, M. P., Wierson, W. A., Solin, S. L., Weiss, T. J., Helmer, J. A., Sandquist, E. J., Shive, H. R., & McGrail, M. A. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.034124 · Cited by 53
“We focused on transcriptional regulators which include epigenetic chromatin remodelers and transcription factors, because a number of studies indicate that regulation of the epigenome is a critical component of oncogenesis (Suva et al., 2013).”
ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming
Li, F., Yuan, Q., Di, W., Xia, X., Liu, Z., Mao, N., Li, L., Li, C., He, J., Li, Y., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137967 · Cited by 50
Darwish, S., Ghazy, E., Heimburg, T., Herp, D., Zeyen, P., Salem-Altintas, R., Ridinger, J., Schmidtkunz, K., Robaa, D., Erdmann, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147535 · Cited by 48
Sanalkumar, R., Dong, R., Lee, L., Xing, Y., Iyer, S., Letovanec, I., Rosa, S. L., Finzi, G., Musolino, E., Papait, R., et al. (2023) · Science Advances · doi:10.1126/sciadv.abo3789 · Cited by 43
Self-citationDmitrijeva, M., Ossowski, S., Serrano, L., & Schaefer, M. H. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky498 · Cited by 76
“Genome-wide epigenetic aberrations displayed by malignant cells include differential DNA methylation, changes in histone post-translational modifications, and abnormalities in chromatin structure (1,5).”
BackgroundRETRACTED: The inner centromere–shugoshin network prevents chromosomal instability
Tanno, Y., Susumu, H., Kawamura, M., Sugimura, H., Honda, T., & Watanabe, Y. (2015) · Science · doi:10.1126/science.aaa2655 · Cited by 49
RetractedPreclinical and clinical evidence for stem cell therapies as treatment for diabetic wounds
Heublein, H., Bader, A., & Giri, S. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.01.005 · Cited by 48
Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target
Agnihotri, N., & Mehta, K. (2016) · Amino Acids · doi:10.1007/s00726-016-2320-2 · Cited by 47
“For example, some epigenetic alterations have been implicated in development of drug resistance and metastasis (Malek et al. 2014; Suva et al. 2013).”
BackgroundMauser, R., Kungulovski, G., Keup, C., Reinhardt, R., & Jeltsch, A. (2017) · Epigenetics & Chromatin · doi:10.1186/s13072-017-0153-1 · Cited by 51
Epigenetic dynamics in cancer stem cell dormancy
Ferrer, A. I., Trinidad, J. R., Sandiford, O. A., Etchegaray, J., & Rameshwar, P. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09882-x · Cited by 47
Epigenetic reprogramming during prostate cancer progression: A perspective from development
Goel, S., Bhatia, V., Biswas, T., & Ateeq, B. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.01.009 · Cited by 47
Giordano, F., Paolì, A., Forestiero, M., Marsico, S., Amicis, F. D., Marrelli, M., Naimo, G. D., Mauro, L., & Panno, M. L. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04015-8 · Cited by 46
Targeting of cancer stem cells by inhibitors of DNA and histone methylation
Momparler, R. L., & Côté, S. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1051220 · Cited by 45
“Both genetic and epigenetic alterations play important roles in cancer development [2,65].”
BackgroundMetabolism in embryonic and cancer stemness
Jang, H., Yang, J., Lee, E., & Cheong, J. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0558-y · Cited by 50
“It is known that alterations in these molecular pathways provide an unlimited proliferative capacity to CSCs (Leal and Lleonart 2013; Suva et al. 2013).”
BackgroundHeterogeneity in cancer stem cells
Wang, A., Chen, L., Li, C., & Zhu, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.040 · Cited by 49
“ylation, as well as altering the chromatin states through chromatin regulators [21,28].”
BackgroundGliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time
Filbin, M. G., & Suvà, M. L. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044208 · Cited by 51
“In addition, many transcription factors that direct developmental decisions also function as oncogenes by promoting the reacquisition of programs required for transformation (86).”
Self-citationOncogenic activity of SOX1 in glioblastoma
García, I., Aldaregia, J., Marjanović, J., Aldaz, P., Moreno‐Cugnon, L., Torres-Bayona, S., Carrasco‐García, E., Garros-Regulez, L., Egaña, L., Rubio, Á., et al. (2017) · Scientific Reports · doi:10.1038/srep46575 · Cited by 46
Evidence of pioneer factor activity of an oncogenic fusion transcription factor
Sunkel, B. D., Wang, M., LaHaye, S., Kelly, B., Fitch, J., Barr, F. G., White, P., & Stanton, B. Z. (2021) · iScience · doi:10.1016/j.isci.2021.102867 · Cited by 51
Epigenetics in Intestinal Epithelial Cell Renewal
Roostaee, A., Benoit, Y. D., Boudjadi, S., & Beaulieu, J. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25401 · Cited by 51
“Indeed, epigenetic mechanisms have important implications in the transcriptional programming and regulation of embryonic and cancer stem cells (Munoz et al., 2012; Suva et al., 2013).”
BackgroundH3K36 methylation maintains cell identity by regulating opposing lineage programmes
Hoetker, M. S., Yagi, M., Stefano, B. D., Langerman, J., Cristea, S., Wong, L. P., Huebner, A. J., Charlton, J., Deng, W., Haggerty, C., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01191-z · Cited by 47
Kasper, L. H., Qu, C., Obenauer, J. C., McGoldrick, D. J., & Brindle, P. K. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku827 · Cited by 43
“Indeed, mutations in epigenetic regulators, including CBP and p300, have been increasingly implicated in cancer (81).”
Backgroundvan der Zwan, Y. G., Rijlaarsdam, M. A., Rossello, F. J., Notini, A. J., de Boer, S., Watkins, D. N., Gillis, A., Dorssers, L. C. J., White, S. J., & Looijenga, L. H. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098330 · Cited by 46
“Deregulation of these tightly controlled processes is known to be involved in the formation and progression of various cancer types [20–24], including GCC [25].”
BackgroundEmerging roles of the histone chaperone CAF-1 in cellular plasticity
Cheloufi, S., & Hochedlinger, K. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.06.004 · Cited by 46
Transcription factors: Time to deliver
Ulasov, A. V., Rosenkranz, A. A., & Sobolev, A. S. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.004 · Cited by 45
Recent advances in the molecular landscape of lung neuroendocrine tumors
Pelosi, G., Bianchi, F., Hofman, P. M., Pattini, L., Ströbel, P., Calabrese, F., Naheed, S., Holden, C., Cave, J., Bohnenberger, H., et al. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1595593 · Cited by 43
“organization of tumors by altering chromatin structure, leading to expansion of intratumor cell heterogeneity upon reprogramming [149,150].”
BackgroundEmerging role of G9a in cancer stemness and promises as a therapeutic target
Haebe, J. R., Bergin, C. J., Sandouka, T., & Benoit, Y. D. (2021) · Oncogenesis · doi:10.1038/s41389-021-00370-7 · Cited by 45
“Considering parallels between CSCs and pluripotency, the concept of oncogenic reprogramming emerged in the literature as an interplay between transcription factors and chromatin regulators which is essential to sustain the CSC phenotype through dynamic cellular plasticity [11, 20, 37, 38] (Fig.”
BackgroundWong, J. Y. Y., Vivo, I. D., Lin, X., Grashow, R. G., Cavallari, J. M., & Christiani, D. C. (2014) · Genetic Epidemiology · doi:10.1002/gepi.21796 · Cited by 44
“This modification is achieved through the addition of methyl groups to cytosine by methyl-transferases and is one of the primary mechanisms regulating expression of human genes [Suva et al., 2013].”
Bioactive lipids in cancer stem cells
Begicevic, R.-R., Arfuso, F., & Falasca, M. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i9.693 · Cited by 43
Lynam‐Lennon, N., Heavey, S., Sommerville, G., Bibby, B. A. S., Ffrench, B., Quinn, J., Gasch, C., O’Leary, J. J., Gallagher, M. F., Reynolds, J. V., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13940 · Cited by 48
“Increasing evidence suggests that the pro-tumorigenic properties of CSCs may result from epigenetic and post-transcriptional alterations, which alter multiple signalling pathways [16, 17].”
BackgroundTranscriptional alterations in glioma result primarily from DNA methylation–independent mechanisms
Court, F., Boiteux, E. L., Fogli, A., Müller-Barthélémy, M., Vaurs‐Barrière, C., Chautard, E., Pereira, B., Biau, J., Kémény, J., Khalil, T., et al. (2019) · Genome Research · doi:10.1101/gr.249219.119 · Cited by 54
“Besides the functional aberrations of H3K27me3 and H3K4me3 writers and erasers documented in many tumors (Suvà et al. 2013; Dawson 2017), these control defects could also result from transcriptional changes in key tissuespecific transcription factors or cofactors.”
BackgroundLiu, Y., Zhang, X., Zhang, Y., Hu, Z., Yang, D., Wang, C., Guo, M., & Cai, Q. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.06.028 · Cited by 40
“Epigenetic modifications are inherited upon somatic cell replication and encompass CpG methylation and histone modifications [29].”
BackgroundCurrent Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs
Liu, F., Wang, C., Gao, Y., Li, X., Tian, F., Zhang, Y., Fu, M., Li, P., Wang, Y., & Wang, F. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0338-8 · Cited by 43
The Δ133p53 Isoforms, Tuners of the p53 Pathway
Joruiz, S. M., Beck, J. A., Horikawa, I., & Harris, C. C. (2020) · Cancers · doi:10.3390/cancers12113422 · Cited by 49
“While promoting cancer stemness, ∆133p53β also favors cellular dysdifferentiation by inducing epithelial to mesenchymal transition (EMT) in cancer cells [49], which involves genome-wide epigenetic reprogramming [77,78].”
BackgroundGenomics, Personalized Medicine, and Pediatrics
Feero, W. G., & Guttmacher, A. E. (2013) · Academic Pediatrics · doi:10.1016/j.acap.2013.06.008 · Cited by 49
“Classical genetics has long recognized the role of molecular modifications to the primary DNA backbone as a determinant of gene expression; in the era of genomics, a wide array of epigenetic changes are known to affect gene expression.(39) The classical pediatric example of methylation resulting in differential gene e…”
Metabolic control of cancer cell stemness: Lessons from iPS cells
Menéndez, J. A. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1022697 · Cited by 40
“Moreover, whereas reprogrammed pluripotent stem cells can acquire oncogenic traits, the converse is not true because oncogenic cells cannot acquire the bona fide pluripotent state possessed by stem cells.15 If the acquisition of stem cell properties in induced pluripotency is closely associated with CSC-driven tumorig…”
BackgroundInfluentialMuthukrishnan, S. D., Kawaguchi, R., Nair, P., Prasad, R., Qin, Y., Johnson, M., Wang, Q., VanderVeer-Harris, N., Pham, A., Alvarado, A. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33943-0 · Cited by 43
Role of autophagy in the maintenance and function of cancer stem cells
Vitale, I., Manic, G., Dandrea, V., & Maria, R. D. (2015) · The International Journal of Developmental Biology · doi:10.1387/ijdb.150082iv · Cited by 40
“…are influenced by genetic, epigenetic and microenvironmental factors(Baccelli and Trumpp, 2012, Chen and Dent, 2014, Curtis et al., 2010, Dieter et al., 2011, Giannoni et al., 2010, Iliopoulos et al., 2011, Sharma et al., 2010, Suva et al., 2013, Todaro et al., 2014, Vermeulen et al., 2010).”
BackgroundGulaia, V. S., Kumeiko, V. V., Shved, N. A., Cicinskas, E., Александрович, Р. С., Ruzov, A. S., & Kagansky, A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00388 · Cited by 42
Yang, X., Miao, B., Wei, C., Dong, R., Gao, P., Zhang, X., Lu, J., Gao, C., Wang, X., Sun, H., et al. (2019) · Cancer Science · doi:10.1111/cas.14037 · Cited by 39
Zhang, A., Tao, W., Zhai, K., Fang, X., Huang, Z., Yu, J. S., Sloan, A. E., Rich, J. N., Zhou, W., & Bao, S. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa150 · Cited by 39
Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter
Kordella, C., Lamprianidou, E., & Kotsianidis, Ι. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650473 · Cited by 45
“ADAR1 upregulation, activated IRF7 translocates into the nucleus inducing the transcription of type-I and III IFN (4), which are then secreted into the tumor”
BackgroundInfluentialPrecision Medicine in Neonates: A Tailored Approach to Neonatal Brain Injury
Tataranno, M. L., Vijlbrief, D. C., Dudink, J., & Benders, M. J. N. L. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.634092 · Cited by 50
“Furthermore, understanding the mechanisms through which the environment exerts changes on genome expression will give new possibilities for new treatments by modulating gene expression and should be further investigated (155).”
BackgroundMetabolism–epigenome crosstalk in physiology and diseases
Hino, S., Nagaoka, K., & Nakao, M. (2013) · Journal of Human Genetics · doi:10.1038/jhg.2013.57 · Cited by 43
The pluripotency factor NANOG promotes the formation of squamous cell carcinomas
Palla, A. R., Piazzolla, D., Alcázar, N., Cañamero, M., Graña‐Castro, O., Goméz-López, G., Domínguez, O., Dueñas, M., Paramio, J. M., & Serrano, M. (2015) · Scientific Reports · doi:10.1038/srep10205 · Cited by 40
Chang, L., Wu, P., Senthilkumar, R., Tian, X., Liu, H., Shen, X., Tao, Z., & Huang, P. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-2000-8 · Cited by 40
“There are many well-established hallmarks of neoplastic cells, which include epigenetic modulation, mutations, aneuploidy, numerical, and structural abnormalities in chromosomes (Suva et al. 2013).”
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications
Sun, R., & Kim, A. H. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10051-5 · Cited by 44
Yang, C. M., Chiba, T., Brill, B., Delis, N., von Manstein, V., Vafaizadeh, V., Oellerich, T., & Groner, B. (2015) · International Journal of Cancer · doi:10.1002/ijc.29606 · Cited by 41
“Reprogramming and cellular transformation share global changes in chromatin structure and DNA methylation and cancer cells might have reverted to a developmentally more primitive epigenetic state.(7,11) The expression of reprogramming factors in vivo provided a link to the transformation process.”
BackgroundBenoit, Y. D., Guezguez, B., Boyd, A. L., & Bhatia, M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2491 · Cited by 44
“While a persistent G9a expression/activity was described in induced pluripotent stem cells and further associated with sustained epigenetic memory (65, 66), a fascinating parallel can be drawn to the differentiation blockade seen in CSCs (67).”
BackgroundPreferential expression of functional IL-17R in glioma stem cells: potential role in self-renewal
Parajuli, P., Anand, R., Mandalaparty, C., Suryadevara, R., Sriranga, P. U., Michelhaugh, S. K., Cazacu, S., Finniss, S., Thakur, A. B., Lum, L. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6847 · Cited by 40
Breast cancer stem cells as last soldiers eluding therapeutic burn: A hard nut to crack
Nilendu, P., Kumar, A., Kumar, A., Pal, J. K., & Sharma, N. K. (2017) · International Journal of Cancer · doi:10.1002/ijc.30898 · Cited by 41
Soto, D. R., Barton, C., Munger, K., & McLaughlin-Drubin, M. E. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006661 · Cited by 39
HOXB7 overexpression in lung cancer is a hallmark of acquired stem-like phenotype
Monterisi, S., Riso, P. L., Russo, K., Bertalot, G., Vecchi, M., Testa, G., Fiore, P. P. D., & Bianchi, F. (2018) · Oncogene · doi:10.1038/s41388-018-0229-9 · Cited by 39
Salvati, A., Gigantino, V., Nassa, G., Giurato, G., Alexandrova, E., Rizzo, F. M., Tarallo, R., & Weisz, A. (2019) · Cancers · doi:10.3390/cancers11111720 · Cited by 38
“Therefore, it represents valuable therapeutic targets [11].”
Broche, J., Kungulovski, G., Bashtrykov, P., Rathert, P., & Jeltsch, A. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1169 · Cited by 49
Jung, M., Pützer, S., Gevensleben, H., Meller, S., Kristiansen, G., & Dietrich, D. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0192-7 · Cited by 42
Franz, M., Payne, W. G., Xing, L., Naidu, D. K., Salas, R., Marshall, V. S., Trumpower, C., Smith, C. A., Steed, D. L., & Robson, M. C. (2008) · PubMed Central · Cited by 41
Lin, Z., Luo, M., Chen, X., He, X., Qian, Y., Lai, S., Si, J., & Chen, S. (2017) · Journal of Cancer · doi:10.7150/jca.18169 · Cited by 38
“The transcriptional silencing of tumor-suppressor genes (TSGs) through aberrant DNA methylation is thought to be a key epigenetic event in the origin of various cancers [7, 8].”
BackgroundBahhaj, F. E., Denis, I., Pichavant, L., Delatouche, R., Collette, F. M., Linot, C., Pouliquen, D., Grégoire, M., Héroguez, V., Blanquart, C., et al. (2016) · Theranostics · doi:10.7150/thno.13725 · Cited by 41
“Overexpression or abnormal activities of these regulators have been linked to human disease like cancers (3) for many years.”
BackgroundXun, J., Wang, D., Shen, L., Gong, J., Gao, R., Du, L., Chang, A., Song, X., Xiang, R., & Tan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.15747 · Cited by 38
“Transcriptional activation and repression maintain a dynamic balance to achieve fine-tuned gene regulation under the control of various factors associated with methylation and acetylation [2, 3, 4].”
BackgroundSalzberg, A. C., Harris‐Becker, A., Popova, E. Y., Keasey, N., Loughran, T. P., Claxton, D. F., & Grigoryev, S. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173723 · Cited by 39
Tang, T., Deng, Y. P., Chen, J., Zhao, Y., Yue, R., Choy, K. W., Wang, C. C., Du, Q., Xu, Y., Han, L., et al. (2016) · Scientific Reports · doi:10.1038/srep30430 · Cited by 37
“Cancer is a genetic disease which involves mutational and epigenetic changes which lead to uncontrollable cell proliferation and differentiation 11,12 .”
Transcriptional and Epigenetic Regulation of KIF14 Overexpression in Ovarian Cancer
Thériault, B. L., Basavarajappa, H. D., Lim, H., Pajovic, S., Gallie, B. L., & Corson, T. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091540 · Cited by 36
“Although warranting further investigation given that promoter methylation is generally seen as a mechanism of transcriptional repression [18], these results raise the intriguing possibility of a feedback mechanism, attempting, but inadequate to reduce KIF14 levels in tumors with high KIF14 expression.”
BackgroundResultSOX3 can promote the malignant behavior of glioblastoma cells
Marjanović, J., Drakulić, D., García, I., Vuković, V., Aldaz, P., Puškaš, N., Nikolić, I., Tasić, G., Raičević, S., Garros-Regulez, L., et al. (2018) · Cellular Oncology · doi:10.1007/s13402-018-0405-5 · Cited by 40
Song, X., Zhao, C., Jiang, L., Lin, S., Bi, J., Wei, Q., Yu, L., Zhao, L., & Wei, M. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.09.025 · Cited by 39
Dixit, D., Prager, B. C., Gimple, R. C., Miller, T. E., Wu, Q., Yomtoubian, S., Kidwell, R. L., Lv, D., Zhao, L., Qiu, Z., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abf3917 · Cited by 37
KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL
Kurt, I. C., Sur‐Erdem, İ., Kaya-Aksoy, E., Cingöz, A., Kazancioglu, S., Kahya, Z., Toparlak, Ö. D., Senbabaoglu, F., Kaya, Z., Ozyerli‐Goknar, E., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.288 · Cited by 38
Ramakrishnan, S., & Пили, Р. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e3182a09e07 · Cited by 36
Li, D., Bi, F., Cao, J.-M., Cao, C., Liu, B., & Yang, Q. F. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-26 · Cited by 37
“In mammals, promoter methylation at CpG dinucleotides is an important feature regulating gene expression [13].”
Differential expression of ten-eleven translocation genes in endometrial cancers
Ciesielski, P., Jóźwiak, P., Wójcik‐Krowiranda, K., Forma, E., Cwonda, Ł., Szczepaniec, S., Bieńkiewicz, A., Bryś, M., & Krześlak, A. (2017) · Tumor Biology · doi:10.1177/1010428317695017 · Cited by 35
Martín-Castillo, B., López‐Bonet, E., Cuyàs, E., Viñas, G., Pernas, S., Dorca, J., & Menéndez, J. A. (2015) · Oncotarget · doi:10.18632/oncotarget.6094 · Cited by 36
“Moreover, there is evidence that more differentiated tumor cells may acquire CSC properties through nuclear reprogramming-like dedifferentiation phenomena; the range or probability of dedifferentiation rates of bulk tumor cells into CSC-like states [132-137], however, is expected to be inversely proportional to the nu…”
BackgroundLiu, S., Yan, B., Lai, W., Chen, L., Xiao, D., Xi, S., Jiang, Y., Dong, X., An, J., Chen, X., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.05.017 · Cited by 39
van Neerven, S. M., Tieken, M., Vermeulen, L., & Bijlsma, M. F. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1098791 · Cited by 38
Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4
Diener, J., Baggiolini, A., Pernebrink, M., Dalcher, D., Lerra, L., Cheng, P. F., Varum, S., Häusel, J., Stierli, S., Treier, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25326-8 · Cited by 34
BRD9-SMAD2/3 Orchestrates Stemness and Tumorigenesis in Pancreatic Ductal Adenocarcinoma
Feng, Y., Cai, L., Pook, M., Liu, F., Chang, C., Mouti, M. A., Nibhani, R., Militi, S., Dunford, J. E., Philpott, M., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.09.021 · Cited by 36
“CSCs are thought to have specific epigenetic mechanisms 18 that regulate their self-renewal, and the formation of CSCs has been postulated to occur as a result of epigenetic events.”
BackgroundLocke, W. J., Zotenko, E., Stirzaker, C., Robinson, M. D., Hinshelwood, R. A., Stone, A. M., Reddel, R. R., Huschtscha, L. I., & Clark, S. J. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0086-0 · Cited by 36
“Alterations in DNA methylation contribute to carcinogenesis via a variety of mechanisms including the silencing of tumour suppressors [1,2] and”
BackgroundOncometabolic Nuclear Reprogramming of Cancer Stemness
Menéndez, J. A., Corominas-Faja, B., Cuyàs, E., García, M. G., Fernández‐Arroyo, S., Fernández, A. F., Joven, J., Fraga, M. F., & Alarcón, T. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.12.012 · Cited by 36
“The inability to stabilize stem cell states and functions by maintaining epigenome integrity, a process in which DNA methylation plays a major role, can trigger pathological self-renewal processes that ultimately lead to cancer (Ohnishi et al., 2014; Suva et al., 2013; Tung and Knoepfler, 2015).”
BackgroundKDM5A Regulates a Translational Program that Controls p53 Protein Expression
Hu, D., Jablonowski, C. M., Cheng, P.-H., AlTahan, A. M., Li, C., Wang, Y., Palmer, L. E., Lan, C., Sun, B., Abu‐Zaid, A., et al. (2018) · iScience · doi:10.1016/j.isci.2018.10.012 · Cited by 38
Messier, T., Boyd, J. R., Gordon, J. A. R., Stein, J. L., Lian, J. B., & Stein, G. S. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25359 · Cited by 33
Metadata
- Authors
- Suvà, M. L., Riggi, N., & Bernstein, B. E.
- Affiliations
- Broad Institute (US)
- Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
- Corresponding author
- Suvà, Mario L.
- Bernstein, Bradley E.
- Venue
- Science
- Published
- 2013-03-29
- Volume
- 339
- Issue
- 6127
- Pages
- 1567-1570
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3821556
- OpenAlex
- W2090757807
- Cited by
- 706
- References
- 64
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 19 · 2023: 40 · 2022: 34 · 2021: 61 · 2020: 62 · 2019: 48 · 2018: 58 · 2017: 72 · 2016: 67 · 2015: 76 · 2014: 85 · 2013: 43
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institute of Environmental Health Sciences (U01ES017155)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- epigenetic reprogramming, cancer, induced pluripotency, transcription factors, chromatin regulators, oncogenic transformation, tumor heterogeneity, cancer stem cells, cell state transitions
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Chromatin, Humans, Neoplasms, Transcription Factors, Neoplastic Stem Cells, DNA Methylation, Pluripotent Stem Cells, Epigenesis, Genetic, Mice, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.